Second-line treatment options in metastatic castration-resistant prostate cancer: A comparison of key trials with recently approved agents

Cancer Treatment Reviews

Volumn 40, Issue 1, 2014, Pages 170-177

  Bahl, Amit ^a   Masson, Susan ^a   Birtle, Alison ^b   Chowdhury, Simon ^c   de Bono, Johann ^d  

^a BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^b LANCASHIRE TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Abiraterone; Cabazitaxel; Castration resistant; Enzalutamide; Metastatic; Prostate cancer

Indexed keywords

ABIRATERONE ACETATE; C 21005; CA 184 043; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; IPILIMUMAB; MITOXANTRONE; ORTERONEL; PLACEBO; PREDNISONE; RADIUM CHLORIDE RA 223; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANEMIA; ARM PAIN; ARTHRALGIA; ASTHENIA; BACKACHE; BONE METASTASIS; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; DIARRHEA; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLUID RETENTION; HEADACHE; HEART DISEASE; HEMATURIA; HOT FLUSH; HUMAN; HYPERTENSION; HYPOKALEMIA; LEG PAIN; LEUKOPENIA; LIMB PAIN; LIVER FUNCTION; LIVER FUNCTION TEST; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SEIZURE; SIDE EFFECT; STUDY DESIGN; THROMBOCYTOPENIA; TREATMENT DURATION; URINARY TRACT INFECTION; VOMITING;

ABIRATERONE; CABAZITAXEL; CASTRATION-RESISTANT; ENZALUTAMIDE; METASTATIC; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84887072136     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.06.008     Document Type: Review

References (37)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer. 2010; Available from: <[Accessed March 2013]. http://globocan.iarc.fr.
2. National Comprehensive Cancer Network. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) Prostate Cancer (Version 3.2012). 2012; Available from: < [Accessed March 2013]. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
3. Horwich A., Parker C., Bangma C., Kataja V. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl 5):v129-v133.
4. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, et al. Guidelines on Prostate Cancer. 2012; Available from: < [Accessed March 2]. http://www.uroweb.org/gls/pdf/08%20Prostate%20Cancer_LR%20March%2013th%202012.pdf.
5. Omlin A, Pezaro C, Mukherji D, et al. Improved Survival in a Cohort of Trial Participants with Metastatic Castration-resistant Prostate Cancer Demonstrates the Need for Updated Prognostic Nomograms. Eur Urol 64, 2013, 300-306.
6. Berthold D.R., Pond G.R., Soban F., de Wit R., Eisenberger M., Tannock I.F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008, 26:242-245.
7. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
8. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
9. Dumontet C., Sikic B.I. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999, 17:1061-1070.
10. O'Neill A.J., Prencipe M., Dowling C., et al. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer 2011, 10:126.
11. JEVTANA® (cabazitaxel) Injection, Prescribing Information, FDA. Available from: [Accessed March 2013]. http://products.sanofi.us/jevtana/jevtana.pdf.
12. JEVTANA® (cabazitaxel) Injection, Summary of Product Characteristics, EMA. < [Accessed March 2013]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002018/WC500104764.pdf.
13. Janssen biotech. Zytiga (abiraterone acetate) tablets for oral administration, Prescribing Information, FDA. Available from: < [Accessed March 2013]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202379lbl.pdf.
14. Janssen biotech. Zytiga (abiraterone acetate) tablets for oral administration, Summary of Product Characteristics, EMA. Available from: < [Accessed March 2013]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002321/WC500112858.pdf.
15. Astellas Pharma US I. Xtandi® (enzalutamide) capsules for oral use, Prescribing Information, FDA. Available from: [Accessed March 2013]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203415lbl.pdf.
16. Parker C., Heinrich D., O'Sullivan J.M., et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Oncol 2012, 30. Abstract 8.
17. Parker C., Nilsson S., Heinrich D., et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J Clin Oncol 2012, 30. Abstract LBA4512.
18. de Bono J.S., Oudard S., Ozguroglu M., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154.
19. de Bono J.S., Logothetis C.J., Molina A., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005.
20. Scher H.I., Halabi S., Tannock I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008, 26:1148-1159.
21. Scher H.I., Fizazi K., Saad F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012, 367:1187-1197.
22. Antonarakis E.S., Eisenberger M.A. Expanding treatment options for metastatic prostate cancer. N Engl J Med 2011, 364:2055-2058.
23. de Bono J.S., Oudard S., Ozguroglu M., et al. A subgroup analysis of the TROPIC trial exploring reason for discontinuation of prior docetaxel and survival outcome of cabazitaxel in metastatic castration-resistant prostate cancer (MCRPC). J Clin Oncol 2011, 29:2-18. Abstract 4526.
24. Chi K.N., Scher H.I., Molina A., et al. Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301 a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2012, 30. Abstract 15.
25. Fizazi K., Scher H.I., Molina A., et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012, 13:983-992.
26. Oudard S., de Bono J.S., Ozguroglu M., et al. Impact of cabazitaxel (CBZ) + prednisone (P; CBZP) on overall survival (OS) at 2 years and in patients (pts) with aggressive disease: post-hoc analyses of TROPIC trial. ESMO 2012, Abstract 933P.
27. Logothetis C.J., Basch E., Molina A., et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012, 13:1207-1217.
28. Carter N., Bryant-Lukosius D., DiCenso A., Blythe J., Neville A.J. The supportive care needs of men with advanced prostate cancer. Oncol Nurs Forum 2011, 38:189-198.
29. Sternberg C.N., Molina A., North S., et al. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Ann Oncol 2012, 24:1017-1025.
30. Esper P., Mo F., Chodak G., Sinner M., Cella D., Pienta K.J. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997, 50:920-928.
31. Malik Z., Di Lorenzo G., Basaran M., et al. Cabazitaxel (Cbz) + prednisone (P; CbzP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D) interim results from compassionate-use programme (CUP) and early-access programme (EAP). Ann Oncol 2012, 23. Abstract 931P.
32. Ryan C.J., Smith M.R., de Bono J.S., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013, 368:138-148.
33. Eisenberger M.A., Hardy-Bessard A.C., Mourey L., et al. Comparison of two doses of cabazitaxel plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen. J Clin Oncol 2012, 30. Abstract TPS4692.
34. ALGETA press release - radium-223. 2011; Available from: < [Accessed March 2013]. http://www.algeta.com/news/news-article/?articleId=1521246.
35. Sartor A.O., Heinrich D., O'Sullivan J.M., et al. Radium-223 chloride. J Clin Oncol 2012, 30. Abstract 4551.
36. Dreicer R., Agus D.B., Bellmunt J., et al. A phase III randomized, double-blind, multicenter trial comparing the investigational agent orteronel (TAK-700) plus prednisone (P) with placebo plus P in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy. J Clin Oncol 2012, 30. Abstract TPS4693.
37. Drake C.G., Scher H.I., Bossi A., et al. CA184-043 A randomized double-blind phase III trial comparing ipilimumab versus placebo following a single dose of radiotherapy (RT) in patients (pts) with castration-resistant prostate cancer (CRPC) who have received prior treatment with docetaxel (D). J Clin Oncol 2012, 30. Abstract TPS4689.